Inhibrx EV/EBITDA
¿Qué es el EV/EBITDA de Inhibrx?
El EV/EBITDA de Inhibrx, Inc. es N/A
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en NASDAQ en comparadas con Inhibrx
¿Qué hace Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Empresas con ev/ebitda similar a Inhibrx
- Wishpond Technologies tiene EV/EBITDA de N/A
- Future Bright tiene EV/EBITDA de N/A
- GoldQuest Mining tiene EV/EBITDA de N/A
- Powercell Sweden Sk ,022 tiene EV/EBITDA de N/A
- O3 Mining tiene EV/EBITDA de N/A
- Tijaria Polypipes tiene EV/EBITDA de N/A
- Inhibrx tiene EV/EBITDA de N/A
- Kidsland International tiene EV/EBITDA de N/A
- Americas Car Mart tiene EV/EBITDA de N/A
- Reabold Resources Plc tiene EV/EBITDA de N/A
- Ausmex Mining tiene EV/EBITDA de N/A
- amalphi ag tiene EV/EBITDA de N/A
- Silver Range Resources tiene EV/EBITDA de N/A